Kenvue (NYSE:KVUE) Price Target Raised to $23.00 at Barclays

Kenvue (NYSE:KVUE - Free Report) had its price objective increased by Barclays from $22.00 to $23.00 in a report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other equities analysts have also recently weighed in on KVUE. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. UBS Group lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Finally, Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $25.33.

Kenvue Trading Up 1.1%

NYSE:KVUE traded up $0.27 during mid-day trading on Monday, hitting $24.15. The company had a trading volume of 19,921,749 shares, compared to its average volume of 16,494,001. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The firm has a market cap of $46.34 billion, a P/E ratio of 45.57, a P/E/G ratio of 2.62 and a beta of 1.02. The business's fifty day moving average is $23.16 and its two-hundred day moving average is $22.59.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the prior year, the business posted $0.28 EPS. Kenvue's revenue was down 3.9% on a year-over-year basis. As a group, research analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB lifted its position in Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after buying an additional 21,222 shares in the last quarter. Alberta Investment Management Corp raised its holdings in Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after acquiring an additional 109,700 shares in the last quarter. Longbow Finance SA raised its holdings in Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after acquiring an additional 13,287 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. grew its stake in Kenvue by 1.4% in the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.